HWHG: HW241045 tablets have received approval for clinical trials
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, HWHG announced that its wholly-owned subsidiary Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for HW241045 tablets issued by the National Medical Products Administration. HW241045 tablets are suitable for the treatment of idiopathic pulmonary fibrosis, and currently, there are no drugs targeting the same site approved for marketing worldwide
According to the Zhitong Finance APP, HWHG (600079.SH) announced that its wholly-owned subsidiary Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for HW241045 tablets issued by the National Medical Products Administration. HW241045 tablets are suitable for the treatment of idiopathic pulmonary fibrosis, and currently, there are no drugs targeting the same site approved for marketing worldwide